Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

709 - Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer


08 Oct 2016


Poster Display


Toshihiko Kaneda


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


T. Kaneda1, H. Yoshioka1, M. Tamiya2, A. Tamiya3, A. Hata4, A. Okada5, T. Niwa1, T. Shiroyama2, M. Kanazu3, T. Ishida1, N. Katakami4

Author affiliations

  • 1 Department Of Respiratory Medicine, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 2 Department Of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 583-8588 - Habikino/JP
  • 3 Department Of Internal Medicine, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 4 Division Of Integrated Oncology, Institute of Biomedical Research and Innovation, 650-0047 - Kobe/JP
  • 5 Department Of Respiratory Medicine, Saiseikai Suita Hospital, 564-0013 - Suita/JP


Abstract 709


Combined analysis from two randomized phase 3 trials showed afatinib improved overall survival (OS) compared with platinum doublets in patients with Exon 19 deletion (Del-19) mutation. However, in patients with Leu858Arg (L858R) point mutation, afatinib efficacy did not differ significantly from chemotherapy. We hypothesized that this discrepancy was due to differential efficacy of cisplatin plus pemetrexed between Del-19 and L858R.


This study is a multicenter retrospective study. We reviewed medical records of patients who had received cisplatin plus pemetrexed as first line chemotherapy. Efficacies were evaluated among epidermal growth factor receptor (EGFR) mutation status: Del-19; L858R; and wild type.


Among 304 patients, 78 (25.7%) harbored EGFR mutations: Del-19 (36/78 patients, 46.2%); and L858R (42/78, 53.8%). Median PFS of L858R group (9.4 months, 95% confidence interval [CI]: 7.0-12.6) was significantly longer than Del-19 group (5.5 months, 95% CI: 3.6-8.6) (p = 0.049). Response rate (RR) and OS presented no significant difference among L858R, Del-19 or wild type. In multivariate analysis, EGFR mutation status (L858R versus Del-19) was the only significant factor for longer PFS (Hazard ratio [HR]: 0.78, 95% CI: 0.62-0.98) (p = 0.033).


Our study indicated better efficacy of cisplatin plus pemetrexed in L858R than in Del-19 patients. This result could be a valuable suggestion to consider better therapeutic strategies for L858R patients.

Clinical trial identification


Legal entity responsible for the study

Kurashiki Central Hospital


Kurashiki Central Hospital


H. Yoshioka: Hiroshige Yoshioka received lecture fees from Chugai, Astra Zeneca, Boehringer Ingelheim, and Eli Lilly. A. Hata: Akito Hata received lecture fees from Chugai, Astra Zeneca, Boehringer Ingelheim, and Eli Lilly. N. Katakami: Nobuyuki Katakami received grants from Astra Zeneca, Chugai, Eli Lilly, and Boehringer Ingelheim, and payment for lectures from Chugai, Boehringer Ingelheim, Astra Zeneca, and Eli Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings